Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 3,390,000 shares, a decrease of 9.4% from the November 15th total of 3,740,000 shares. Based on an average daily trading volume, of 761,800 shares, the short-interest ratio is presently 4.4 days.
Wall Street Analyst Weigh In
A number of research firms have commented on ALNY. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Raymond James upped their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Cantor Fitzgerald restated a “neutral” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. Chardan Capital reaffirmed a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Finally, StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $298.09.
Read Our Latest Research Report on Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Stock Performance
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same period in the previous year, the firm posted $1.15 earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was down 33.3% compared to the same quarter last year. Analysts forecast that Alnylam Pharmaceuticals will post -2.21 EPS for the current fiscal year.
Insider Transactions at Alnylam Pharmaceuticals
In related news, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the sale, the chief marketing officer now directly owns 17,457 shares in the company, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,122 shares of company stock worth $2,540,455. Corporate insiders own 1.50% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the stock. Ashton Thomas Private Wealth LLC purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at $26,000. Huntington National Bank grew its stake in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares in the last quarter. Hollencrest Capital Management purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $29,000. Washington Trust Advisors Inc. bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at about $42,000. Finally, True Wealth Design LLC boosted its holdings in Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 153 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Further Reading
- Five stocks we like better than Alnylam Pharmaceuticals
- What is the Nasdaq? Complete Overview with History
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- What Are Dividend Contenders? Investing in Dividend Contenders
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- Health Care Stocks Explained: Why You Might Want to Invest
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.